Thus, when comparing the outcomes of chronic treatment of SHR with URB597 (FAAH blockade only) and JZL195 (dual FAAH/MAGL blockade), increasing 2-AG levels by the inhibition of MAGL might become a new therapeutic option in hypertension. The gene discussed is FAAH; the disease is Hypertension.